Literature DB >> 19701217

Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.

Ferdinando Fusco1, Riccardo Sicuteri, Andrea Rossi, Stathis Kontodimas, Jose Maria Haro, Ciro Imbimbo, Vincenzo Mirone.   

Abstract

The Erectile Dysfunction Observational Study (EDOS) is a 6-months observational prospective multicentric study enrolling men with erectile dysfunction (ED) who asked, to be started on a treatment or to change a previous treatment. Aims of the study were to analyse the pattern of treatment and compare the efficacy of treatments used. Patients were enrolled during a normal hospital visit and were prescribed a treatment for ED. They were asked at baseline and after 3 and 6 months, to answer a set of questions from the International Index of Erectile Function, Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) and Short Form of the Psychological and Interpersonal Relationships Scale questionnaires (SF-PAIRS). Clinicians were free to prescribe any therapy for ED available in the market, and to change therapy at any time during the study. Out of 1 338 patients, available for analysis at 6 months, 624 (47%) changed their treatment during the study and 714 (53%) continued with the drug prescribed at baseline. Patients assuming tadalafil had a significantly higher probability of maintaining the same treatment compared to sildenafil or vardenafil. There was no clinically significant difference in terms of efficacy, patient satisfaction, self-confidence and spontaneity between the different inhibitors of PDE5. The 'time concerns' domain score of SF-PAIRS, was statistically better in patients assuming tadalafil. In conclusion sildenafil, vardenafil and tadalafil show similar efficacy in the clinical practice. However, patients receiving tadalafil display a lower risk to discontinue or change the treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701217      PMCID: PMC3735015          DOI: 10.1038/aja.2009.48

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  22 in total

Review 1.  The 'effectiveness' scale--therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report.

Authors:  C Carson; F Giuliano; I Goldstein; D Hatzichristou; W Hellstrom; T Lue; F Montorsi; R Munarriz; A Nehra; H Porst; R Rosen
Journal:  Int J Impot Res       Date:  2004-06       Impact factor: 2.896

2.  On life satisfaction in male erectile dysfunction.

Authors:  A R Fugl-Meyer; G Lodnert; I B Bränholm; K S Fugl-Meyer
Journal:  Int J Impot Res       Date:  1997-09       Impact factor: 2.896

Review 3.  Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research.

Authors:  K B Wells
Journal:  Am J Psychiatry       Date:  1999-01       Impact factor: 18.112

4.  Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials.

Authors:  V Fonseca; A Seftel; J Denne; P Fredlund
Journal:  Diabetologia       Date:  2004-11-25       Impact factor: 10.122

5.  Sildenafil citrate after radical retropubic prostatectomy.

Authors:  B H Lowentritt; P T Scardino; B J Miles; F J Orejuela; E C Schatte; K M Slawin; S P Elliott; E D Kim
Journal:  J Urol       Date:  1999-11       Impact factor: 7.450

6.  Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial.

Authors:  Francesco Montorsi; Harin Padma Nathan; Andrew McCullough; Gerald B Brock; Gregory Broderick; Sanjeev Ahuja; Steve Whitaker; Amy Hoover; Donna Novack; Aileen Murphy; Lucio Varanese
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

7.  Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction.

Authors:  C Stief; H Porst; I Sáenz De Tejada; E Ulbrich; M Beneke
Journal:  Int J Clin Pract       Date:  2004-03       Impact factor: 2.503

8.  Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group.

Authors:  M S Rendell; J Rajfer; P A Wicker; M D Smith
Journal:  JAMA       Date:  1999-02-03       Impact factor: 56.272

9.  Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients.

Authors:  G Del Popolo; V Li Marzi; N Mondaini; G Lombardi
Journal:  Spinal Cord       Date:  2004-11       Impact factor: 2.772

10.  A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.

Authors:  Alexander von Keitz; Jacob Rajfer; Scott Segal; Aileen Murphy; Jonathan Denne; Timothy Costigan; Daniel Lockhart; Charles M Beasley; Jeffrey T Emmick
Journal:  Eur Urol       Date:  2004-04       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.